• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药效学的系统方法。II:格列本脲药效学及最佳药物递送的估计

A system approach to pharmacodynamics. II: Glyburide pharmacodynamics and estimation of optimal drug delivery.

作者信息

Gillespie W R, Veng-Pedersen P, Antal E J, Phillips J P

机构信息

College of Pharmacy, University of Iowa, Iowa City 52242.

出版信息

J Pharm Sci. 1988 Jan;77(1):48-55. doi: 10.1002/jps.2600770109.

DOI:10.1002/jps.2600770109
PMID:3126291
Abstract

A system approach to the analysis of pharmacodynamic systems is applied to the relationship between the glyburide serum concentration (Cd) and a resulting pharmacologic effect response, that is, the C-peptide serum concentration (Cc) in patients with non-insulin dependent diabetes mellitus (NIDDM). Glyburide, glucose, and C-peptide serum concentrations were measured in eight patients with NIDDM following each of five treatments: Treatment A: one glyburide 5-mg tablet (formulation 1); Treatment B: one glyburide 5-mg tablet (formulation 2); Treatment C: glyburide solution as an intragastric infusion (4.67 mg over 12 h); Treatment D: glyburide solution as an intragastric infusion (9.33 mg over 12 h); and Treatment E: no glyburide. The overall relationship between the C-peptide (Cc), glyburide (Cd), and glucose (Cg) serum concentrations is successfully described by operator equations of the form, Cc(t) = t-infinity psi p(t-u)phi t(Cd(u), Cg(u)) du or Cc(t) = t-infinity psi p(t-u)phi t(Cd(u), Cg(u),u) du. The forms of the individual functions are selected empirically based on the results of the present study and those of previous investigations, and are estimated by conventional curve-fitting procedures. The resulting operator equations are used to describe glyburide pharmacodynamics in NIDDM patients and to estimate the optimal glyburide systemic concentration and delivery rate profiles for such patients based on pharmacodynamic response.

摘要

一种用于分析药效学系统的系统方法被应用于非胰岛素依赖型糖尿病(NIDDM)患者中格列本脲血清浓度(Cd)与所产生的药理效应反应(即C肽血清浓度(Cc))之间的关系。在八名NIDDM患者接受以下五种治疗中的每一种后,测量了格列本脲、葡萄糖和C肽的血清浓度:治疗A:一片5毫克格列本脲片剂(制剂1);治疗B:一片5毫克格列本脲片剂(制剂2);治疗C:作为胃内输注的格列本脲溶液(12小时内输注4.67毫克);治疗D:作为胃内输注的格列本脲溶液(12小时内输注9.33毫克);以及治疗E:不使用格列本脲。C肽(Cc)、格列本脲(Cd)和葡萄糖(Cg)血清浓度之间的总体关系通过以下形式的算子方程成功描述:Cc(t) = t到负无穷 psi p(t - u)phi t(Cd(u), Cg(u)) du 或 Cc(t) = t到负无穷 psi p(t - u)phi t(Cd(u), Cg(u), u) du。各个函数的形式是根据本研究结果和先前研究结果凭经验选择的,并通过传统的曲线拟合程序进行估计。所得的算子方程用于描述NIDDM患者中的格列本脲药效学,并根据药效学反应估计此类患者的最佳格列本脲全身浓度和给药速率曲线。

相似文献

1
A system approach to pharmacodynamics. II: Glyburide pharmacodynamics and estimation of optimal drug delivery.药效学的系统方法。II:格列本脲药效学及最佳药物递送的估计
J Pharm Sci. 1988 Jan;77(1):48-55. doi: 10.1002/jps.2600770109.
2
Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM.非胰岛素依赖型糖尿病患者短期和长期使用格列本脲治疗的药代动力学和药效学比较。
Diabetes Care. 1994 Nov;17(11):1300-6. doi: 10.2337/diacare.17.11.1300.
3
Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients.格列本脲对胰岛素治疗的糖尿病患者血糖控制、胰岛素需求及葡萄糖代谢的影响。
Diabetes. 1987 Feb;36(2):136-46. doi: 10.2337/diab.36.2.136.
4
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.氟伐他汀与口服降糖药在健康受试者及非胰岛素依赖型糖尿病患者中无相互作用。
Am J Cardiol. 1995 Jul 13;76(2):29A-32A. doi: 10.1016/s0002-9149(05)80012-8.
5
Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.格列本脲可增强β细胞对葡萄糖的反应性,但不能纠正非胰岛素依赖型糖尿病患者胰岛素分泌的异常模式。
J Clin Endocrinol Metab. 1989 Sep;69(3):571-6. doi: 10.1210/jcem-69-3-571.
6
Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea.
Diabetes Care. 1987 Sep-Oct;10(5):545-54. doi: 10.2337/diacare.10.5.545.
7
Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus.格列本脲在非胰岛素依赖型糖尿病年轻及老年患者中的药代动力学和药效学
Ann Pharmacother. 1996 May;30(5):472-5. doi: 10.1177/106002809603000507.
8
The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics.
Eur J Clin Pharmacol. 1993;45(5):459-63. doi: 10.1007/BF00315518.
9
Effects of glyburide on in vivo insulin-mediated glucose disposal.格列本脲对体内胰岛素介导的葡萄糖处置的影响。
Am J Med. 1990 Aug 20;89(2A):44S-50S; discussion 51S-53S. doi: 10.1016/0002-9343(90)90335-b.
10
Mechanism of improvement in glucose metabolism after chronic glyburide therapy.慢性格列本脲治疗后葡萄糖代谢改善的机制。
Diabetes. 1984 Sep;33(9):838-45. doi: 10.2337/diab.33.9.838.

引用本文的文献

1
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.理解药代动力学/药效动力学关系中的滞后环难题。
J Pharm Pharm Sci. 2014;17(1):34-91.
2
Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.药代动力学中的线性和非线性系统方法:它们能提供多少价值?II. 响应映射算子(RMO)方法。
J Pharmacokinet Biopharm. 1988 Oct;16(5):543-71. doi: 10.1007/BF01062384.
3
Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.
J Pharmacokinet Biopharm. 1988 Aug;16(4):413-72. doi: 10.1007/BF01062554.
4
The use of kinetic-dynamic interactions in the evaluation of drugs.动力学-动态相互作用在药物评估中的应用。
Psychopharmacology (Berl). 1990;100(4):433-50. doi: 10.1007/BF02243994.
5
Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.整合反应波动的体内药效学数学模型:在多巴胺模拟药物DCN 203-922催乳素抑制作用中的应用
J Pharmacokinet Biopharm. 1991 Jun;19(3):287-309. doi: 10.1007/BF03036252.